3880.HK
MEDTIDE
HK$21.74
-1.63%
2026-05-29
About MEDTIDE
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
Key Fundamentals
P/E Ratio
11.56
Forward P/E
8.14
EPS (TTM)
HK$1.88
ROE
22.8%
Revenue Growth (YoY)
29.2%
Profit Margin
38.1%
Debt/Equity
1.94
Price/Book
1.69
Market Cap
HK$3.08B
Avg Volume (10D)
108K
Recent Breakout Signals
No recent breakout signals detected for 3880.HK.
Recent Price Range (60 Days)
60D High
HK$25.52
60D Low
HK$21.04
Avg Volume
105K
Latest Close
HK$21.74
Get breakout alerts for 3880.HK
Sign up for Breakout Scanner to receive daily notifications when 3880.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
MEDTIDE (3880.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 3880.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 3880.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.